文献速递前列腺癌

前列腺癌寡复发盆腔淋巴结患者接受高剂量选择性挽救性放疗联合激素治疗的长期结局与复发模式:OLIGOPELVIS(GETUG-P07)

Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
PubMed 文献 · Eur Urol · 2024-03-14

开放标签II期试验纳入67例前列腺癌寡复发(<6个)盆腔淋巴结患者,评估6个月雄激素剥夺治疗(ADT)联合选择性盆腔放疗的5年结局。中位随访6.1年(95%CI:5.9-6.3),5年无进展生存率39%、生化复发无生存率31%、免ADT生存率64%;45例出现进展,复发最常见部位为腹主动脉旁淋巴结(M1a占50%)。联合治疗似乎延长肿瘤控制且毒性有限。

要点

  • 67例前列腺癌寡复发盆腔淋巴结患者接受6个月ADT联合选择性盆腔放疗。
  • 5年无进展生存率39%、生化复发无生存率31%、免ADT生存率64%。
  • 45例进展患者中,M1a(腹主动脉旁淋巴结)为最常见复发部位(50%)。

核心结论

  • 联合选择性盆腔放疗和ADT似乎延长肿瘤控制且毒性有限。
  • 5年时三分之一患者未发生生化复发。
  • 主要复发部位为腹主动脉旁淋巴结。

研究设计与样本

  • 开放标签II期试验(OLIGOPELVIS GETUG-P07),分析5年结局。
  • 共纳入67例前列腺癌寡复发(<6个)盆腔淋巴结患者。
  • 干预为6个月ADT联合选择性盆腔放疗。
  • 进展定义为连续两次前列腺特异性抗原水平高于入组时水平和/或按RECIST 1.1标准临床进展和/或任何原因死亡。

主要发现

  • 中位随访6.1年(95%CI:5.9-6.3)。
  • 3年、4年、5年2级及以上泌尿生殖毒性和胃肠道毒性分别影响15%、9%、4%和2%、3%、4%的无进展患者。
  • 5年无进展生存率、生化复发无生存率和免ADT生存率分别为39%、31%和64%。
  • 共45例患者出现进展,38例有以下临床进展部位:局部18%、N1 29%、M1a 50%、M1b 32%、M1c 11%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) is a mainstay in metastatic prostate cancer, while additional salvage radiotherapy may offer prolonged remission for patients with regional node relapses. We performed an open-label, phase II trial to assess the long-term outcomes and patterns of relapse of 6-months ADT and elective pelvic radiotherapy in men with oligorecurrent (<6) pelvic nodes in prostate cancer (Oligopelvis GETUG-P07). METHODS: We analyzed the 5-yr outcomes. Progression was defined as two consecutive prostate-specific antigen levels above the level at inclusion and/or clinical progression as per RECIST 1.1 and/or death from any cause. KEY FINDINGS AND LIMITATIONS: Sixty-seven patients were recruited. The median follow-up was 6.1 yr (95%CI: 5.9-6.3). Grade 2+ 3-yr, 4-yr and 5-yr genito-urinary and gastro-intestinal toxicities affected 15%, 9%, 4% and 2%, 3%, 4% of non-progressive patients, respectively. 5-yr progression-free, biochemical relapse-free and ADT-free survivals were 39%, 31% and 64%, respectively. In total, 45 patients had progression and 38 had the following clinical progression: local (18%), N1 (29%), M1a (50%), M1b (32%) and M1c (11%). CONCLUSIONS AND CLINICAL IMPLICATIONS: Finally, combined elective pelvic radiotherapy and ADT appeared to prolong tumor control with limited toxicity. At 5 years, one third of patients had not relapsed biochemically. The major site of relapse was para-aortic lymph nodes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Vaugier L, Morvan C, Pasquier D, et al. Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07). Eur Urol. 2024. PMID: 38490854. doi:10.1016/j.eururo.2024.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。